SPTCL Without HLH and Low Tumor Burden: What to Do When First-Line Therapy Does Not Achieve a Response
This protocol addresses the clinical situation in which a patient with subcutaneous panniculitis-like T-cell lymphoma — presenting without hemophagocytic lymphohistiocytosis (HLH) and with low tumor burden (localized or limited subcutaneous disease) — has not achieved an adequate response to first-line treatment.
Clinical Scenario
The patient presents with SPTCL without HLH and limited subcutaneous disease. In this setting, immunomodulatory approaches are preferred over chemotherapy. The absence of HLH is a key factor that shapes the treatment strategy.
First-Line Therapy Did Not Achieve CR or PR
This protocol is triggered when first-line therapy — which may have included single agents such as cyclosporine, methotrexate, or bexarotene (with or without prednisone), or local therapy such as involved-site radiotherapy (ISRT) or intralesional steroids — failed to produce a complete response (CR) or partial response (PR).
The failure to reach these response milestones is the escalation trigger for the next therapeutic step outlined here.
Next-Step Treatment Approach (Partial Overview)
The approach involves switching to an alternate therapy not previously used — including the possibility of local therapy if not yet employed — and, where other options have been insufficient, certain additional agents may be considered with or without prednisone. The full sequencing, agent selection criteria, and complete regimen detail are available in the structured protocol.
References
- SPTCL Without HLH and Low Tumor Burden (Localized or Limited Subcutaneous Disease)
- While chemotherapy may be considered for patients presenting with HLH, immunomodulatory therapies are considered for patients who present without HLH.
- Patients who do not achieve an adequate response to first-line therapy may be given a different first-line therapy or a local therapy (if not given as a first-line therapy) to achieve disease control.
- Further, pralatrexate or romidepsin can be given with or without prednisone as additional therapies if other treatment options are insufficient.
View source ↗